Quince Therapeutics reports $5.8M cash, $16.4M debt; engages LifeSci Capital for reverse merger

Quince Therapeutics, Inc.

As of Dec 31, 2025, cash and short-term investments total $17.7M; EIB Loan outstanding $16.4M.
Lead drug candidate eDSP failed NEAT trial; no other products; no meaningful operations.
Engaged LifeSci Capital on Feb 9, 2026 to evaluate strategic alternatives including reverse merger.
Common stock closing bid price below $1.00 since Jan 29, 2026; Nasdaq delisting risk.
May need bankruptcy protection if reverse merger fails; Bank has not invoked MAC clause yet.

item 2.02item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.